title: The clinical significance of drug interactions between dermatological and psychoactive medications.
abstract: Dermatological disease is commonly associated with psychological morbidity because of its visible nature. The burden of living with a chronic dermatological illness can contribute to the development of psychiatric illness and conversely, such conditions can result in the exacerbation of preexisting dermatological disease. It may also reduce a patient's compliance to treatment, result in loss to follow-up and a decreased level of functioning and quality of life. In dermatological patients who suffer from psychiatric symptoms, medical management used in their treatment may have significant interactions with systemic medications used to treat their dermatological condition. A well-known example of this is lithium's ability to exacerbate psoriasis. Such interactions can result in suboptimal treatment of their psychiatric and/or dermatological condition. The present paper aimed to review the literature for documented interactions and the level of clinical significance between dermatological and psychoactive medications. Such information is clinically relevant to the practicing dermatologist in order to minimize adverse effects and drug-drug interactions in dermatological patients.
authors: Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
authors: John W
authors: JW
authors: Frew
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D000962:Antimalarials / Q000494:pharmacology; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D003879:Dermatologic Agents / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D011619:Psychotropic Drugs / Q000009:adverse effects*
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000962:Antimalarials; D065692:Cytochrome P-450 CYP3A Inhibitors; D003879:Dermatologic Agents; D011619:Psychotropic Drugs; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
keywords: adverse effects; drug interactions; psychoactive medications